Activity mode for artificial pancreas system
A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.
1. A wearable drug delivery system, comprising:
a reservoir configured to store a liquid drug;
a pump mechanism operable to expel doses of the liquid drug from the reservoir;
an inertial measurement unit operable to detect an activity level of a user; and
a controller communicatively coupled to the pump mechanism and the inertial measurement unit, wherein the controller is operable to:
automatically initiate an activity mode of operation based on a determined activity level change based on an input from the inertial measurement unit exceeding one or more activity mode thresholds, wherein the activity mode of operation is selected from a plurality of modes corresponding to different levels of activity;
modify parameters used in calculation of doses of the liquid drug to be delivered to a user; and
output a signal to cause actuation of delivery of the liquid drug via the pump mechanism according to the set activity mode.
2. The wearable drug delivery device of claim 1 , wherein the activity mode of operation is a automatically turned off after a period of time after initiation.
3. The wearable drug delivery system of claim 1 , wherein the activity mode of operation can be manually turned off by the user.
4. The wearable drug delivery system of claim 1 , wherein the activity level of the user must also surpass an activity duration threshold before the activity mode of operation is automatically initiated.
5. The wearable drug delivery system of claim 1 , wherein the controller is further operable to generate an alert via a user interface requesting confirmation of initiation of the activity mode of operation.
6. The wearable drug delivery system of claim 1 , further comprising:
a glucose sensor, and
the calculation of doses of the liquid drug to be delivered to the user is further based on glucose level readings output from the glucose sensor.
7. The wearable drug delivery system of claim 6 , wherein the glucose sensor is co-located with the controller.
8. The wearable drug delivery system of claim 1 , further comprising:
a smart accessory device comprising a communication device, a processor, and a memory.
9. The wearable drug delivery system of claim 8 , wherein the smart accessory device is a smartwatch.
10. The wearable drug delivery system of claim 8 , wherein the smart accessory device is a wearable fitness device.
11. The wearable drug delivery system of claim 1 , wherein the controller is further operable to:
in response to setting the activity mode to a first activity mode, setting a maximum insulin delivery to approximately 1 to 3 times an original basal rate of the user.
12. The wearable drug delivery system of claim 1 , wherein the controller is further operable to:
in response to setting the activity mode to a first activity mode, setting a basal rate input to an automated drug delivery algorithm equal to approximately 50% to 90% of an original basal rate of the user.
13. The wearable drug delivery system of claim 1 , wherein the controller is further operable to:
in response to setting the activity mode to a second activity mode, setting a target setpoint within a range of approximately 100 mg/dL to 120 mg/dL.
14. The wearable drug delivery system of claim 1 , wherein the controller is further operable to:
in response to setting the activity mode to a second activity mode, setting a maximum insulin delivery to approximately 3 to 6 times an original basal rate of the user.
15. The wearable drug delivery system of claim 1 , wherein the controller is further operable to:
in response to setting the activity mode to a second mode, reducing a hyperglycemia alarm threshold for triggering alarms for any glucose values above a predetermined value and duration.
16. The wearable drug delivery system of claim 15 , wherein the predetermined value and duration are approximately 250 to 350 mg/dL and greater than approximately 30 minutes, respectively.
17. The wearable drug delivery system of claim 6 , wherein the controller is further operable to:
initiate a hyperglycemia protect mode based on inputs received from the glucose sensor,
wherein initiation of the hyperglycemia protect mode causes further modification of parameters used in calculation of doses of the liquid drug to be delivered to the user.
18. The wearable drug delivery system of claim 6 , wherein the controller is further operable to:
initiate a hypoglycemia protect mode based on inputs received from the glucose sensor,
wherein initiation of the hypoglycemia protect mode causes further modification of parameters used in calculation of doses of the liquid drug to be delivered to the user.